



an Open Access Journal by MDPI

Translational Discoveries in T-cell Lymphomas

Guest Editors:

Dr. Danilo Fiore

Department of Molecular
Medicine and Medical
Biotechnology, University of
Naples Federico II, Via Tommaso
De Amicis 95, Laboratori IEOS,
CNR, Scala C, III piano, 80131
Naples, Italy

Dr. Luca Vincenzo Cappelli

Department of Pathology and
Laboratory Medicine, Weill
Cornell Medicine, New York, NY
10065, USA

Deadline for manuscript
submissions:

closed (15 December 2022)

Message from the Guest Editors

Despite the introduction of successful novel therapeutic approaches in the treatment of human lymphomas, the survival of patients with T-cell lymphomas (TCL) is dismal. As of today, remarkable advancements have been impaired by TCL rarity and the limited knowledge of pathogenetic mechanisms, together with a lack of reliable pre-clinical models. Recent efforts have led to dramatic improvements in TCL functional and genetic stratification, leading to a fast-evolving scenario. In this new perspective, we predict that the integration of TCL phenotypic and molecular features will foster translational discoveries to be tested in new informative pre-clinical models, ultimately refining diagnosis and improving the clinical outcome of patients.

This Special Issue aims to collect research articles and reviews from researchers investigating different aspects of TCL tumorigenesis, with a focus on translational discoveries accounting for new targeted agents, immunotherapies and chimeric antigen receptor (CAR)-adoptive strategies (CAR-T/CAR-NK cells).



mdpi.com/si/72743

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI